Drug: Uptravi (selexipag)

Manufacturer: Johnson & Johnson

Route of Administration: Oral

Site of Care: Outpatient

Approved Indication: treatment of pulmonary arterial hypertension (PAH, WHO group 1) to delay disease progression and reduce the risk of hospitalization for PAH

Disease: pulmonary arterial hypertension

Therapeutic Area: Pulmonary

Enrollment Form Link: Enrollment Form

Phone Number: 866-228-3546

Fax Number: 866-279-0669

Product Website: uptravi.com